BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2019 11:29:12 AM | Browse: 770 | Download: 1035
 |
Received |
|
2019-01-10 01:04 |
|
Peer-Review Started |
|
2019-01-10 05:23 |
|
To Make the First Decision |
|
2019-02-18 02:58 |
|
Return for Revision |
|
2019-03-04 07:05 |
|
Revised |
|
2019-06-05 14:15 |
|
Second Decision |
|
2019-06-10 02:12 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-06-10 22:14 |
|
Articles in Press |
|
2019-06-10 22:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-07-05 09:45 |
|
Publish the Manuscript Online |
|
2019-07-06 11:29 |
| ISSN |
2307-8960 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Cholestatic liver diseases: An era of emerging therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hrishikesh Samant, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, Moheb Boktor, Wuttiporn Manatsathit and Jonathan Steven Alexander |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jonathan Steven Alexander, FACG, PhD, Professor, Department of Molecular and Cellular Physiology, Louisiana State University, School of Medicine, 1501 Kings Highway, Shreveport, LA 71103, United States. jalexa@lsuhsc.edu |
| Key Words |
Bile acids; Drug therapy; Cholestatic liver disease; Nuclear receptor agonists |
| Core Tip |
Anti-cholestatic therapeutic options now go beyond ursodeoxycholic acid (UDCA) and target nuclear receptors regulating bile acid (farnesoid X receptor) and G protein-coupled receptor and fibroblast growth factor-19. Additionally enterohepatic bile acid transporters and norUDCA represent potential targets in cholestatic disease. |
| Publish Date |
2019-07-06 11:29 |
| Citation |
Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, Alexander JS. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019; 7(13): 1571-1581 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i13/1571.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i13.1571 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
